Vasculitis & polymyalgia rheumatica
Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy
Authors' conclusion
Within 6 months of RIT, rates of survival without severe infection were similar in newly diagnosed ANCA-positive AAV patients treated with RTX or CYC, but survival rates without infections of any severity appeared to be lower with RTX treatment.
Study context
- Population
- Consecutive adults newly diagnosed with anti-neutrophil cytoplasmic antibody (ANCA)-positive GPA or MPA, Caen University Hospital, January 2006–December 2019
- Participants
- 145 adults
- Exposure
- Rituximab (RTX) vs CYC as remission-induction therapy
- RTXn = 27
- CYCn = 118reference
- Outcome
- Survival without severe infection
- Follow-up
- 6 months after RIT
Methodological detailssingle-centre, consecutive patients, multivariate Cox analysis
- Single-centre
- Consecutive patients
- Multivariate Cox analysis
Main finding
As reported in the abstract
6 months
- Similar in both groups
- RTX vs CYC: P = 0.69
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Survival without infections of any severity · 6 months | P = 0.005 |
Survival without infections of any severity · 6 months
- Lower in the RTX group
Risk factors at diagnosis for severe infection (multivariate analysis)
- Chronic urinary tract disease, dialysis, and absence of trimethoprim-sulfamethoxazole prophylaxis
- P < 0.01 each
Safety
Infections recorded overall · 6 months
- Severe infections
- 37
- Infections of any severity
- 65
Original publication
Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy. Scand J Rheumatol. Published 20 January 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →